Suscribirse

A Pragmatic Study of Cardiovascular Disease During Long-Term COVID-19 - 11/02/25

Doi : 10.1016/j.amjmed.2024.03.011 
James F. Howick, MD a, , Petar Saric, MD, PharmD b, Mohamed Elwazir, MB, ChB b, Darrell B. Newman, MD b, Patricia A. Pellikka, MD b, Annelise S. Howick, BA c, John C. O'Horo, MD, MPH d, e, Leslie T. Cooper, MD f, Abhishek J. Deshmukh, MBBS b, Ravindra Ganesh, MBBS, MD g, Ryan Hurt, MD, PhD g, Bernard Gersh, MB, ChB, DPhil, FRCP, MACC b, John P. Bois, MD b, h
a Department of Internal Medicine 
b Department of Cardiovascular Medicine 
c Department of Emergency Medicine 
d Division of Public Health, Infectious Diseases and Occupational Medicine 
e Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minn 
f Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Fla 
g Division of General Internal Medicine 
h Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minn 

Requests for reprints should be addressed to James F. Howick V, MD, Department of Internal Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905.Department of Internal MedicineMayo Clinic200 1st St SWRochesterMN55905

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Many patients diagnosed with COVID-19 have persistent cardiovascular symptoms, but whether this represents a true cardiac process is unclear. This study assessed whether symptoms associated with long COVID among patients referred for cardiovascular evaluation are associated with objective abnormalities on cardiac testing to explain their clinical presentation.

Methods

A retrospective cohort study of 40,462 unique patients diagnosed with COVID-19 at our tertiary referral was conducted and identified 363 patients with persistent cardiovascular symptoms a minimum of 4 weeks after polymerase chain reaction confirmed COVID-19 infection. Patients had no cardiovascular symptoms prior to COVID-19 infection. Each patient was referred for cardiovascular evaluation at a tertiary referral center. The incidence and etiology of abnormalities on cardiovascular testing among patients with long COVID symptoms are reported here. The cohort was subsequently divided into 3 categories based on the dominant circulating severe acute respiratory syndrome coronavirus 2 variant at the time of initial infection for further analysis.

Results

Among 40,462 unique patients diagnosed with COVID-19 at our tertiary referral center from April 2020 to March 2022, 363 (0.9%) patients with long COVID were evaluated by Cardiology for possible cardiac sequelae from COVID and formed the main study cohort. Of these, 229 (63%) were vaccinated and 47 (12.9%) had severe initial infection, receiving inpatient treatment for COVID prior to developing long COVID symptoms. Symptoms were associated with a cardiac cause in 85 (23.4%), of which 52 (14.3%) were attributed to COVID; 39 (10.7%) with new cardiac disease from COVID, and 13 (3.6%) to worsening of pre-existing cardiac disease after COVID infection. The median troponin change in 45 patients with troponin measurements within 4 weeks of acute infection was +4 ng/dL (9 to 13 ng/dL). Among the total cohort with long COVID, 83.7% were diagnosed during the pre-Delta phase, 13.2% during the Delta phase, and 3.1% during the Omicron phase of the pandemic. There were 6 cases of myocarditis, 11 rhythm disorders, 8 cases of pericarditis, 5 suspected cases of endothelial dysfunction, and 33 cases of autonomic dysfunction.

Conclusion

This pragmatic retrospective cohort study suggests that patients with long COVID referred for cardiovascular evaluation infrequently have new, objective cardiovascular disease to explain their clinical presentation. A multidisciplinary, patient-centered approach is warranted for symptom management along with conservative use of diagnostic testing.

El texto completo de este artículo está disponible en PDF.

Keywords : Cardiovascular disease, Long COVID, Pandemic


Esquema


 Funding: None.
 Conflicts of Interest: None.
 Authorship: All authors had access to the data and a role in writing the manuscript. JFH: Writing – review & editing, original draft, Investigation, Formal analysis; PS: Writing – review & editing, Methodology, Investigation, Data curation; ME: Writing – review & editing, Methodology, Investigation, Formal analysis; DBN: Writing – review & editing, Supervision, Investigation, Conceptualization; PAP: Writing – review & editing, Supervision; ASH: Writing – review & editing, original draft, Investigation, Formal analysis; JCO: Writing – review & editing, Supervision, Data curation; LTC: Writing – review & editing, Supervision; AJD: Writing – review & editing; RG: Writing – review & editing, Supervision; RH: Writing – review & editing, Supervision; BG: Writing – review & editing, original draft, Supervision; JPB: Writing – review & editing, original draft, Supervision.


© 2024  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 138 - N° 3

P. 532 - mars 2025 Regresar al número
Artículo precedente Artículo precedente
  • Risk of Major Adverse Cardiovascular Events After SARS-CoV-2 Infection in British Columbia: A Population-Based Study
  • Héctor Alexander Velásquez García, Stanley Wong, Dahn Jeong, Mawuena Binka, Zaeema Naveed, James Wilton, Nathaniel Mark Hawkins, Naveed Zafar Janjua
| Artículo siguiente Artículo siguiente
  • Social Networks as a Key Health Determinant in Acute Illness Recovery: A Lesson from the COVID-19 Pandemic
  • Di Pan, Jihui L. Diaz, Karissa Weidman, Julia Graham, Parag Goyal, Mangala Rajan, Jennifer Lau, Laura Pinheiro, Leena Rachid, Will Simmons, Edward J. Schenck, Monika M. Safford, Lindsay Lief

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.